I get the impression NOX are keen to continue with the other programs. Graham mentioned that the other programs wouldn't compete with LuPIN.
So I think the most likely is a licensing or partnership deal with Novartis to get the product to market in the next 12 months, while allowing NOX to continue to persue other markets.
That or an asset sale of the IP for LuPIN specifically.
I get the impression NOX are keen to continue with the other...
Add NOX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $30.68M | |||
| Open | High | Low | Value | Volume |
| 10.5¢ | 10.5¢ | 10.5¢ | $11.41K | 108.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 123424 | 10.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 11.5¢ | 50000 | 1 |
View Market Depth
| Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
| NOX (ASX) Chart |